XENE
Xenon Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Buy"
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XENE
Xenon Pharmaceuticals Inc.
A clinical stage biopharmaceutical company that developing therapeutics for neurological disorders
Biological Technology
11/05/1996
11/05/2014
NASDAQ Stock Exchange
327
12-31
Common stock
200-3650 Gilmore Way, Burnaby, British Columbia V5G 4W8
--
Xenon Pharmaceuticals Inc., was incorporated in British Columbia on November 5, 1996 under the Business Corporations Act (British Columbia) under the name of its predecessor, Xenon Bioresearch Inc. The company is a clinical-stage biopharmaceutical company that discovers and develops a pipeline of differentiated therapies for orphans. The company intends to commercialize itself for a larger market and intends to establish partnerships with global pharmaceutical companies. In order to develop symptomatic drugs, the company has established a core enabling discovery platform by studying rare human diseases with extreme characteristics, including diseases caused by ion channel mutations, also known as ion channel gene mutation diseases. The company has an integrated platform that includes internal functions such as human genetics, small molecule drug discovery and preclinical and clinical development.
Earnings Call
Q1/2025
Estimate EPS-0.9
Actual EPS-0.83
Estimate Revenue1.91M
Actual Revenue7.50M
Xenon Pharmaceuticals' 2025 Q1 Earnings Call: Navigating Contradictions in X-TOLE2 and MDD Study Timelines
May 20,2025 07:45
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.99
Actual EPS-1.07
Estimate Revenue--
Actual Revenue0
Xenon Pharmaceuticals' Q2 2025: Navigating Contradictions in X-TOLE2 Enrollment, Dosing, and Safety Strategies
Aug 11,2025 11:52
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-1.16
Actual EPS-1.15
Estimate Revenue--
Actual Revenue0
Xenon Pharmaceuticals' Q3 2025 Earnings Call Contradictions Emerge on X-TOLE2 Study Size, Top Line Data, NDA Filing, Enrollment Timing, and Bipolar Depression Study Design
Nov 04,2025 02:52
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
XENE has released its 2025 Q3 earnings. EPS was reported at -1.15, versus the expected -1.16, beating expectations. The chart below visualizes how XENE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
